Pyridinium,1-ethyl-2-[[3-ethyl-5-(3-methyl-2(3H)-benzothiazolylidene)-4-oxo-2-thiazolidinylidene]methyl]-

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: Pyridinium,1-ethyl-2-[[3-ethyl-5-(3-methyl-2(3H)-benzothiazolylidene)-4-oxo-2-thiazolidinylidene]methyl]-
• 英文别名: (2Z,5E)-3-ethyl-2-[(1-ethylpyridin-1-ium-2-yl)methylidene]-5-(3-methyl-1,3-benzothiazol-2-ylidene)-1,3-thiazolidin-4-one
• 化学式: C21H22N3OS2+
• 分子量: 396.6
• InChiKey: QLYHOWIZHHZGPV-XUTLUUPISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] PHARMACEUTICAL COMPOUNDS AND USE OF SAME IN CANCER AND TAUOPATHIES<br/>[FR] COMPOSÉS PHARMACEUTIQUES ET LEUR UTILISATION DANS LE CANCER ET LES TAUOPATHIES
  申请人：UNIV MICHIGAN

  公开号：WO2014134243A1

  公开（公告）日：2014-09-04

  Disclosed are compounds of formula (l)-(V): where the substituents are as provided herein. Further disclosed are methods of inhibiting tau aggregation, treating or ameliorating a tauopathy or cancer by administration of such a compound. Tau is a microtubule-binding protein that accumulates in a number of neurodegenerative disorders, including frontotemporal dementia and Alzheimer's disease (AD). The presence of abnormal tau correlates with neuron loss and memory deficits in patients with AD and other neurodegenerative disorders that involve tau accumulation.

  披露了公式(l)-(V)的化合物：其中取代基如本文所述。进一步披露了通过给予这种化合物治疗或缓解tau聚集、tau病变或癌症的方法。Tau是一种微管结合蛋白，在多种神经退行性疾病中积累，包括额颞叶痴呆和阿尔茨海默病（AD）。异常tau的存在与AD患者和其他涉及tau积累的神经退行性疾病患者的神经元丧失和记忆缺陷相关。
• Anti-Trypanosomiasis Agent
  申请人：Ihara Masataka

  公开号：US20080045574A1

  公开（公告）日：2008-02-21

  The present invention is to provide an anti-trypanosomiasis agent having a high selective toxicity, and high preventing or treating effect against trypanosomiasis, comprising a compound shown by the following general formula (1) as an active ingredient (wherein R 1 and R 2 each independently represents a hydrogen atom, halogen atom, hydroxyl group, oxygen atom, C 1-5 alkyl group, C 1-5 alkoxy group, C 5-8 aryl group, C 5-8 aryloxy group, C 2-6 alkoxycarbonyl group or C 2-6 alkylaminocarbonyl group, and may be bound to each other; R 3 , R 4 , and R 5 each independently represents a C 1-5 alkyl group or C 5-8 aryl group; R 6 and R 7 each independently represents a hydrogen atom, halogen atom, hydroxyl group, oxygen atom, C 1-8 alkyl group, C 1-5 alkoxy group, C 5-8 aryl group, C 5-8 aryloxy group, or C 2-6 alkoxycarbonyl group, and may be bound to each other; Y and Z each independently represents an atom group necessary to form a 5- or 6-membered heterocycle; m and n each represent 0 or 1; Q represents a physiologically acceptable anion; k represents an integer of 0 to 2, necessary to make the electric charge of the whole molecule 0).
• PHARMACEUTICAL COMPOSITION COMPRISING AZARHODACYANINE COMPOUND AS ACTIVE INGREDIENT
  申请人：Ihara Masataka

  公开号：US20090076067A1

  公开（公告）日：2009-03-19

  The object of the invention is to provide pharmaceutical composition that can be used as a therapeutic and/or prophylactic agent. Particularly, the pharmaceutical composition of the invention has significant therapeutic effect and survival benefit for the disease caused by parasitic protozoa, and selective toxicity against the causative protozoa. The pharmaceutical composition comprises a compound represented by general formula (1). Particularly, the invention relates to a composition that is an effective therapeutic/prophylactic agent for malaria, leishmania, African sleeping sickness, Chagas disease, toxoplasmosis lymphatic filariasis, babesiosis, and coccidiosis, and a novel compound contained therein.
• US20140275169A1
  申请人：——

  公开号：US20140275169A1

  公开（公告）日：2014-09-18
• PHARMACEUTICAL COMPOUNDS AND USE OF SAME IN CANCER AND TAUOPATHIES
  申请人：REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20160000770A1

  公开（公告）日：2016-01-07

  Disclosed are compounds of formula (1)-(V): where the substituents are as provided herein. Further disclosed are methods of inhibiting tau aggregation, treating or ameliorating a tauopathy or cancer by administration of such a compound. Tau is a microtubule-binding protein that accumulates in a number of neurodegenerative disorders, including frontotemporal dementia and Alzheimer's disease (AD). The presence of abnormal tau correlates with neuron loss and memory deficits in patients with AD and other neurodegenerative disorders that involve tau accumulation.